☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
The Lancet Oncology
Innovent Publishes the Results of Sintilimab + IBI305 (bevacizumab- biosimilar) in P-II/III ORIENT-32 Study as 1L Treatment for HC...
June 22, 2021
Load more...
Back to Home
Modal title
×
Modal body text goes here.